Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

To the Editors

V. Cottin, C. Khouatra, R. Lazor, P. Canu, J-F. Cordier
European Respiratory Journal 2009 33: 450-452; DOI: 10.1183/09031936.00161808
V. Cottin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Khouatra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Lazor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Canu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J-F. Cordier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

We read with interest the study by Stolz et al. 1 reporting on the lack of improvement of exercise capacity caused by the dual endothelin-1 antagonist bosentan in patients with severe chronic obstructive pulmonary disease (COPD) and absence of severe pulmonary hypertension (PH) at rest. Pulmonary vasodilators, like bosentan or sildenafil, may not work in patients with COPD-related PH, a condition dominated by right ventricular diastolic dysfunction with normal cardiac output 2.

However, Stolz et al. 1 acknowledged that these results may not apply to uncommon cases of severe PH associated with COPD. Thus it was suggested that PH-specific treatment first be studied in the subgroup of patients identified by Chaouat et al. 3, with severe disproportionate PH 4, 5, arbitrarily defined by a mean pulmonary arterial pressure (P̄ pa) of >40 mmHg 3.

Herein, we report dramatic functional improvement with bosentan therapy in a patient with COPD and severe disproportionate PH. A 53-yr-old female with a history of obesity (body mass index 41 kg·m−2), type II diabetes, hypothyroidism and acute pulmonary embolism 3 yrs previously, was followed for severe COPD. She was a former smoker (30 pack-yrs) and her dyspnoea was functional class III. After two episodes of right cardiac failure 3 yrs previously she was receiving furosemide 80 mg·day−1. Obstructive sleep apnoea syndrome was ruled out. High-resolution computed tomography of the chest showed mild diffuse emphysema. Pulmonary function tests showed severe airflow obstruction with air trapping and hyperinflation: forced vital capacity (FVC) 2.3 L (76% predicted), total lung capacity 6.3 L (128% pred), forced expiratory volume in one second (FEV1) 0.84 L (34% pred), FEV1/FVC 37%, residual volume 4.0 L (226% pred) and carbon monoxide diffusion capacity was 87% pred. The patient had been on long-term oxygen therapy (2.5 L·min−1) for 3 yrs, with arterial oxygen tension (Pa,O2) on long-term oxygen therapy of 11.0 kPa, but elevated carbon dioxide arterial tension (Pa,CO2; table 1⇓).

View this table:
  • View inline
  • View popup
Table 1—

Patient characteristics and outcome with bosentan

PH suggested by echocardiography was confirmed by right heart catheterisation, demonstrating a pulmonary artery pressure of 110/50 mmHg (mean 65 mmHg), with a transpulmonary gradient of 49 mmHg, cardiac index of 2.6 L·min−1·m−2 and pulmonary vascular resistance (PVR) of 739 dyn·s·cm−5 without response to inhaled NO. No chronic thromboembolic disease or other cause of PH was found. The patient had not taken anorexigens and left ventricular function was normal. Since the contribution of PH to exercise limitation was considered significant and dyspnoea gradually increased, therapy with oral bosentan was initiated at 62.5 mg b.i.d. for 4 weeks, then increased to 125 mg b.i.d. Oral anticoagulation was initiated and long-term oxygen therapy was kept unchanged.

Within 4 weeks of bosentan initiation, dyspnoea significantly decreased to functional class II. The patient was able to resume activities such as home cleaning, going shopping and going to the beach. She could climb one flight of stairs without stopping (as opposed to no more than 5–10 steps before treatment) and resumed indoor biking. However, arterial blood gas analysis showed increased Pa,CO2 (9.6 kPa), and nocturnal noninvasive nasal ventilation was initiated 1 yr after the diagnosis of PH. Clinical improvement persisted throughout follow-up. Bosentan was well tolerated.

The 6-min walk test distance had improved from 198 to 360 m 2 yrs after initiating bosentan therapy. Right heart cavities were no longer dilated at echocardiography, and right heart catheterisation showed that PVR decreased to 214 dyn·s·cm−5, cardiac index increased to 3.7 L·min−1·m−2 and P̄ pa was 34 mmHg. Pulmonary function tests were unchanged (table 1⇑).

Improvement of PH was not explained by weight loss 6, or by changes in Pa,O2. Interestingly, in the study by Stolz et al. 1, bosentan therapy was associated with a significant decrease in Pa,O2, presumably related to increased ventilation–perfusion mismatching, intrapulmonary right-to-left microshunting (itself due to quantitative perfusion augmentation or fluid retention) and/or the reduction of peripheral carotid body sensitivity with a decrease in hypoxic ventilatory response. Indeed, Pa,CO2 was further increased in our patient while on bosentan, leading to the initiation of noninvasive ventilation.

This observation suggests that clinical trials are warranted to evaluate the possible efficacy of pulmonary hypertension-specific therapy in patients with chronic obstructive pulmonary disease and disproportionate pulmonary hypertension and characterise possible responders 3–5. However, detrimental effects on gas exchange should be carefully monitored.

Statement of interest

Statements of interest for V. Cottin, R. Lazor and J-F. Cordier can be found at www.erj.ersjournals.com/misc/statements.shtml

    • © ERS Journals Ltd

    References

    1. ↵
      Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:619–628.
      OpenUrlAbstract/FREE Full Text
    2. ↵
      Hoeper MM. Treating pulmonary hypertension in COPD: where do we start?. Eur Respir J 2008;32:541–542.
      OpenUrlFREE Full Text
    3. ↵
      Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189–194.
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005;127:1531–1536.
      OpenUrlCrossRefPubMedWeb of Science
    5. ↵
      Weitzenblum E, Delcroix M. Treatment of pulmonary hypertension in chronic obstructive pulmonary disease. In: Siafakas N, ed. Management of Chronic Obstructive Pulmonary Disease. Eur Respir Mon 2006;38:313–324.
      OpenUrl
    6. ↵
      Mathier MA, Zhang J, Ramanathan RC. Dramatic functional improvement following bariatric surgery in a patient with pulmonary arterial hypertension and morbid obesity. Chest 2008;133:789–792.
      OpenUrlCrossRefPubMed
    PreviousNext
    Back to top
    View this article with LENS
    Vol 33 Issue 2 Table of Contents
    European Respiratory Journal: 33 (2)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    To the Editors
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    To the Editors
    V. Cottin, C. Khouatra, R. Lazor, P. Canu, J-F. Cordier
    European Respiratory Journal Feb 2009, 33 (2) 450-452; DOI: 10.1183/09031936.00161808

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    To the Editors
    V. Cottin, C. Khouatra, R. Lazor, P. Canu, J-F. Cordier
    European Respiratory Journal Feb 2009, 33 (2) 450-452; DOI: 10.1183/09031936.00161808
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Statement of interest
      • References
    • Figures & Data
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
    • Optimised surveillance of bronchial dysplasia in risky population
    • Reply: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society